Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 336

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 336
---
 on the closing market price of our common stock on the date of
grant, and is recognized as expense on a straight-line basis over the period of vesting. Forfeitures are recognized as a reduction of
share-based compensation expense as they occur. At December 31, 2024 and 2023, there were no outstanding share-based awards with market
or performance conditions.

In addition, we periodically grant RSUs to non-employee
consultants, which we account for in accordance with the authoritative guidance for share-based compensation. The cost of non-employee
services received in exchange for share-based awards are measured based on either the fair value of the consideration received, or the
fair value of the share-based award issued, whichever is more reliably measurable.

     F-10 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023 (continued)

Basic and Diluted Income (Loss) Per Common Share

Basic income (loss) per common share is computed by
dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted earnings per common share is computed by dividing our net income (loss) available to common stockholders by the sum of the weighted
average number of common shares outstanding during the period, plus the potential dilutive effects of unvested RSUs and shares of common
stock expected to be issued under our Convertible Notes and Series A and B Preferred during the period.

The potential dilutive effect of unvested RSUs outstanding
during the period are calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. The
potential dilutive effect of our Convertible Notes and Series B Preferred Stock outstanding during the period is calculated using the
if-converted method assuming the conversion of Convertible Notes and Series B Preferred as of the earliest period reported or at the date
of issuance, if later, but are excluded if their effect is anti-dilutive.

The following table presents common share equivalents
excluded from the calculation of diluted net income (loss) per share for the years ended December 31, 2024 and 2023, as the effect of
their inclusion would have been anti-dilutive during periods of net loss:

    Schedule of anti dilutive shares 

    Year Ended December 31, 2024  
    Year Ended